Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial.
BreastAug 7, 2026 (epub)
Frédérique Penault-Llorca, Amelie Lusque, Thomas Filleron et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the predictive value of the SET ER/PR index for docetaxel benefit in node-positive, hormone receptor-positive breast cancer patients from the PACS-01 trial. The study found that patients with a SET ER/PR index ≥ 1.50 had worse outcomes with docetaxel compared to anthracycline-based therapy, with a hazard ratio of 3.16 (95% CI 1.28-7.85).
Key findings
- SET ER/PR index ≥ 1.50 was associated with worse outcomes with 3FEC+3D versus 6FEC (HR 3.16, 95% CI 1.28-7.85).
- No predictive value was found for the Recurrence Score in assessing treatment benefit.
- Continuous SET ER/PR showed significant interaction with treatment on distant recurrence-free interval (P interaction = 0.028).
- The predefined <0.75 cut point for SET ER/PR was not predictive (P interaction = 0.668).
Why it matters
Identifying which patients benefit from specific chemotherapy regimens is crucial for optimizing treatment strategies in hormone receptor-positive breast cancer. This study highlights the potential of the SET ER/PR index in guiding therapy decisions.